AR088273A1 - Composicion contenida dentro de un inhalador farmaceutico presurizado de dosis medida - Google Patents

Composicion contenida dentro de un inhalador farmaceutico presurizado de dosis medida

Info

Publication number
AR088273A1
AR088273A1 ARP120103749A ARP120103749A AR088273A1 AR 088273 A1 AR088273 A1 AR 088273A1 AR P120103749 A ARP120103749 A AR P120103749A AR P120103749 A ARP120103749 A AR P120103749A AR 088273 A1 AR088273 A1 AR 088273A1
Authority
AR
Argentina
Prior art keywords
composition
dose inhaler
composition contained
measure
active ingredient
Prior art date
Application number
ARP120103749A
Other languages
English (en)
Inventor
Toneguzzo Fernando
Cesar Veiga Julio
Original Assignee
Pablo Cassara S R L Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pablo Cassara S R L Lab filed Critical Pablo Cassara S R L Lab
Publication of AR088273A1 publication Critical patent/AR088273A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composición contenida dentro de un inhalador farmacéutico presurizado de dosis medida, que contiene una suspensión líquida, y que comprende: al menos un ingrediente farmacéutico activo; al menos un propelente sin clorofluorocarburo; polvo de lactosa en partículas de diámetro medio superior a 1 mm y en una concentración que oscila entre 0,01 y 2% p/p de la suspensión líquida; y al menos un estabilizador de la suspensión seleccionado de un grupo formado por polietilen glicol, ácido oleico, trioleato de sorbitán, povidona, poloxámeros y una combinación de ellos. Reivindicación 6: La composición de las reivindicaciones 1 ó 2, caracterizada porque el ingrediente activo es budesonida. Reivindicación 7: La composición de las reivindicaciones 1 ó 2, caracterizada porque el ingrediente activo es fumarato de formoterol dihidrato o una sal o un hidrato del mismo. Reivindicación 8: La composición de las reivindicaciones 1 ó 2, caracterizada porque el ingrediente activo es budesonida y fumarato de formoterol dihidrato o una sal o hidrato del mismo.
ARP120103749A 2011-10-31 2012-10-09 Composicion contenida dentro de un inhalador farmaceutico presurizado de dosis medida AR088273A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/286,171 US20130104881A1 (en) 2011-10-31 2011-10-31 Stabilized Metered Dose Inhaler

Publications (1)

Publication Number Publication Date
AR088273A1 true AR088273A1 (es) 2014-05-21

Family

ID=48171108

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103749A AR088273A1 (es) 2011-10-31 2012-10-09 Composicion contenida dentro de un inhalador farmaceutico presurizado de dosis medida

Country Status (3)

Country Link
US (1) US20130104881A1 (es)
AR (1) AR088273A1 (es)
MX (1) MX364924B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015010121A2 (pt) * 2012-11-30 2017-07-11 Hoffmann La Roche inibidores de quinase de tirosina de bruton
GB201306984D0 (en) * 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
WO2015200049A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
AU2016263444B2 (en) * 2015-05-21 2019-03-07 Island Breeze Systems Ca, Llc Propellant based metered dose inhaler and food applicators and applicators
CN110840864B (zh) * 2019-12-20 2022-02-22 广州健康元呼吸药物工程技术有限公司 一种β2受体激动剂吸入气雾剂及包含该吸入气雾剂的产品

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070851A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
EP2327403A3 (en) * 2007-02-19 2011-08-31 Cipla Limited Pharmaceutical combinations of at least two bronchodilators
NZ590256A (en) * 2008-07-11 2013-03-28 Map Pharmaceuticals Inc INHALER CANISTER WITH PRIMELESS VALVE AND VOLUME LESS THAN 10mL

Also Published As

Publication number Publication date
US20130104881A1 (en) 2013-05-02
MX364924B (es) 2019-05-14
MX2012012755A (es) 2013-04-29

Similar Documents

Publication Publication Date Title
PE20121396A1 (es) Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol
AR070834A1 (es) Dosificacion y formulacion de aclidinio para el tratamiento de trastornos respiratorios
AR088273A1 (es) Composicion contenida dentro de un inhalador farmaceutico presurizado de dosis medida
PE20160681A1 (es) Formulacion de premezcla de dexmedetomidina
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
AR101593A2 (es) Formulación superfina de formoterol
CO6630082A2 (es) Tratamiento de lupus nefritis usando laquinimod
PE20091672A1 (es) Nueva dosificacion y formulacion
PH12017500479A1 (en) Liquid inhalation formulation comprising prl554
EA201390049A1 (ru) Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы
MX2013013440A (es) Composiciones, metodos y sistemas para suministro respiratorio de dos o mas agentes activos.
MX2015004604A (es) Antagonistas de los receptores metabotropicos de glutamato 2/3 (mglu2/3) para el tratamiento de los trastornos autistas.
CO6220902A2 (es) Formulacion en polvo del valganciclovir
PE20191240A1 (es) Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios
NI201400139A (es) Nueva forma de dosificación y formulación de abediterol
AR091161A1 (es) Composicion farmaceutica para inhalacion, metodo, uso
CO6270213A2 (es) Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion
CO7170181A2 (es) Nueva composición de alfentanilo para el tratamiento del dolor agudo
PE20240808A1 (es) Composiciones, metodos y sistemas para la administracion de farmacos en aerosol
MX2018005876A (es) Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas.
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа
AR121758A2 (es) Composición farmacéutica que puede suministrarse desde un inhalador dosificador
UA111123C2 (uk) Застосування комбінованого терапевтичного засобу для лікування риніту
MX2019001701A (es) Composicion farmaceutica de dosis fija que comprende mometasona y azelastina.

Legal Events

Date Code Title Description
FC Refusal